A new era of unapproved drugs -: The case of Abigail Alliance v Von Eschenbach

被引:40
作者
Jacobson, Peter D.
Parmet, Wendy E.
机构
[1] Univ Michigan, Sch Publ Hlth, Ctr Law Eth & Hlth, Ann Arbor, MI 48109 USA
[2] Northeastern Univ, Sch Law, Boston, MA 02115 USA
来源
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION | 2007年 / 297卷 / 02期
关键词
D O I
10.1001/jama.297.2.205
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
引用
收藏
页码:205 / 208
页数:4
相关论文
共 8 条
[1]  
*AB ALL, AB STOR
[2]  
[Anonymous], FUT DRUG SAF PROM PR
[3]  
Costanza ME, 1995, CLIN CANCER RES, V1, P699
[4]   Risks in new drug development: Approval success rates for investigational drugs [J].
DiMasi, JA .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 2001, 69 (05) :297-307
[5]   Can the pharmaceutical industry reduce attrition rates? [J].
Kola, I ;
Landis, J .
NATURE REVIEWS DRUG DISCOVERY, 2004, 3 (08) :711-715
[6]   Listen to all the voices:: an advocate's perspective on early access to investigational therapies [J].
Mayer, Musa .
CLINICAL TRIALS, 2006, 3 (02) :149-153
[7]  
PILON R, 2006, WALL STREET J 0603, P9
[8]  
2005, WALL STREET J 1115, pA22